John Evans

Wonderful NYT story about our BEAM-302 data in @nytimes @ginakolata provides a clear summary of the significance of this data, along with perspectives from leaders in the AATD and genetic disease fields We will accelerate this program for patients nytimes.com/2025/03/10/hea…

This May Be the Most Important Medical Story of the Decade nytimes.com/2026/04/09/opi…

Today, Beam announced publication of data from the ongoing Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) for treatment of sickle cell disease with severe vaso-occlusive crises in The New England Journal of Medicine.

Beam CEO @john_evans3 joins @RtwLp on their latest podcast episode to talk gene editing—from CRISPR to base editing—and the future of one‑time cures. Listen to the episode below to learn more about the work behind the #BeamTeam! #DaretoBeam

We are currently opening up our 50-patient pivotal cohort for an intended accelerated approval filing in the US, with first dose on track for 2H26 Thank you to the entire Beam team, the AATD community, and all AATD patients for partnering with us to advance BEAM-302

Finally we now have strong evidence of inducibility of the corrected gene One 60mg patient went from 6.9uM baseline to a new floor of 15.9uM after BEAM-302 treatment Then during a respiratory infection in month 8 their AAT levels went up further to 29.5uM AAT -- and still 95% M

Excited to share our updated BEAM-302 data! This is now a robust, industry-leading data set with over 29 total patients treated. globenewswire.com/news-release/2…

Conference call at 8am with more details Joining us will be Dr. Kiran Musunuru of UPenn to discuss our PKU program as well as novel regulatory pathways for precision gene editing

Cash runway is now into mid-2029 assuming a minimum draw of $200M on the Sixth Street facility We are excited to continue our momentum in building the leading precision genetic medicine company

Several important updates today: First, we are announcing our next liver program, BEAM-304, for the treatment of PKU. BEAM-304 uses an innovative platform approach, creating custom mutation corrections for different patients within a single program. globenewswire.com/news-release/2…

I'm honored to be included in the @washingtonpost Next 50, representing a remarkable community—scientists, physicians, caregivers, and the patients who inspire us—working together to bring the life-saving promise of therapeutic gene editing to those living with genetic diseases. Profile by Carolyn Johnson: drive.google.com/file/d/1GJYKnZ… washingtonpost.com/post-next/inte…

As well as Waseem Quasim and Alyssa Tapley (GOSH London): time.com/collections/ti…

It’s also great to see other honorees included who are helping pioneer the amazing clinical progress with base editing, including Kiran Musunuru and Rebecca Ahrens-Nicklas (UPenn/CHOP, Philadelphia): time.com/collections/ti…

On behalf of the Beam team, I’m honored to be included in the TIME100 2026 World’s Most Influential Leaders in Health for our work on base editing for the treatment of alpha-1 antitrypsin deficiency and for sickle cell disease: time.com/collections/ti…

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: @BeamTx's CEO @john_evans3 shares an update on based editing for alpha-1 antitrypsin deficiency, sickle cell disease, and more. $BEAM Full video: biotechtv.com/post/beam-ther…